drugset / Trial / NCT01408576
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of the study is assess the safety and tolerability of long-term epratuzumab treatment in subjects with Systemic Lupus Erythematosus (SLE)
Timeline
- Start
- 2011-07
- Primary completion
- 2016-02
- Completion
- 2016-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epratuzumab | Monoclonal antibody | 600 mg | Other |
| Subject | Epratuzumab | Monoclonal antibody | 1200 mg | Other |